Neurotensin receptors in pancreatic ductal carcinomas

EJNMMI Research

Table 1 NT receptors in ductal pancreatic cancer primaries and liver metastases

Patient number	Primary	Metastasis	Comments
Patient number	Receptor density dpm/mg tissue	Receptor density dpm/mg tissue	Comments
Primary only
1	8,335 (9,392; 7,278)^a
2	0
3	0
4	6,194 (6,317; 6,071) het^a
5	9,600 (9,301; 9,899)^a
Primary + metastasis of same patient
6	9,310 (9,157; 9,462) het^a	0
7	3,053 (2,953; 3,152) het^a	3,982 (4,584; 3,379) het^a
8	10,274 (10,626; 9,921)^a	5,084 (5,174; 4,993) het^a
9	0	0	Chemotherapy before resection
10	6,026 (6,243; 5,808)^a	0
11	6,145 (6,405; 5,884)	4,482 (4,978; 3,986)
Metastasis only
12		10,866 (11,013; 10,719)^a
13		8,611 (8,189; 9,033)^a
14		8,517 (8,791; 8,243)^a
15		0
16		0
17		6,124 (6,075; 6,172) het^a	Chemotherapy before resection
18		13,207 (13,169; 13,245)^a
19		13,235 (13,047; 13,422)^a
20		9,753 (9,872; 9,634)^a
21		0
22		6,842 (8,250; 5,433)^a
23		10,684 (12,298; 9,070)^a
24		0
25		0
26		7,671 (7,259; 8,083)
27		7,828 (7,959; 7,697)
28		0
Mean ± SEM of positive cancers	7,367 ± 860	8,349 ± 791
Total incidence	8/11 (73%)	14/23 (61%)

het, heterogeneous NT-R distribution. Values represent NT-R density (dpm per mg tissue) as mean of two separate experiments with individual values in parenthesis. ^aIn addition to the displacement by neurotensin, full displacement by SR48692 was observed in these tumors.